RCT - Efficacy of Intravenous Vitamin C Versus Placebo on Estimated Blood Loss in Total Abdominal Hysterectomy

NCT ID: NCT07335432

Last Updated: 2026-01-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-01

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Intervention Group: Received two 1 gm doses of Vitamin C intravenously (IV). first Dose: At midnight on the day of surgery. Second Dose: Immediately after the surgical incision. Control Group: Received two doses of a normal saline intravenously (IV) at the exact same times.

The primary outcome was to compare intraoperative blood loss between patients who received intravenous Vitamin C and those who did not, following an abdominal hysterectomy under general anesthesia.

Intraoperative estimated blood loss (EBL) was meticulously quantified by weighing surgical gauze and measuring suction canister volumes.

The secondary outcomes were to evaluate the potential benefits of Vitamin C administration, including:

* Reduction in the decline of hematocrit levels after surgery.
* Reduction of the length of hospital stay

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myoma;Uterus Adenomyosis of Uterus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental: Vitamin C

Intervention Group: Received two 1 gm doses of Vitamin C intravenously (IV). first Dose: At midnight on the day of surgery. Second Dose: Immediately after the surgical incision. Control Group: Received two doses of a normal saline intravenously (IV) at the exact same times.

Group Type EXPERIMENTAL

Vitamin C (Ascorbic Acid)

Intervention Type DIETARY_SUPPLEMENT

Received two 1 gm doses of Vitamin C intravenously (IV).

first Dose: At midnight on the day of surgery.

Second Dose: Immediately after the surgical incision.

Placebo

Group Type EXPERIMENTAL

Vitamin C (Ascorbic Acid)

Intervention Type DIETARY_SUPPLEMENT

Received two 1 gm doses of Vitamin C intravenously (IV).

first Dose: At midnight on the day of surgery.

Second Dose: Immediately after the surgical incision.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin C (Ascorbic Acid)

Received two 1 gm doses of Vitamin C intravenously (IV).

first Dose: At midnight on the day of surgery.

Second Dose: Immediately after the surgical incision.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female patients who underwent total abdominal hysterectomy

* No bleeding tendency.
* No history of anticoagulant or thrombolytic drug use
* No contraindications to vitamin C supplementation

Exclusion Criteria

* Inability to communicate in the Thai language.

* Underwent total abdominal hysterectomy due to gynecologic malignancy.
* Required emergency total abdominal hysterectomy.
* History of vitamin C supplementation within 2 weeks prior to surgery.
* History of smoking.
* Previous abdominal surgery, such as bowel surgery, cesarean section
Minimum Eligible Age

20 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Queen Savang Vadhana Memorial Hospital, Thailand

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Aektanat Tawornkitpanich

M.D.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Queen Savang Vadhana Memorial hospital

Si Racha, Changwat Chon Buri, Thailand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

012/2567

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.